{"id":655516,"date":"2023-06-14T13:06:01","date_gmt":"2023-06-14T13:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=655516"},"modified":"2023-06-14T13:06:01","modified_gmt":"2023-06-14T13:06:01","slug":"microvascular-angina-clinical-trials-growth-and-key-companiescompanies-predictive-bioscience-centogene-gmbh-pacific-edge-limited-coloplast-as","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/microvascular-angina-clinical-trials-growth-and-key-companiescompanies-predictive-bioscience-centogene-gmbh-pacific-edge-limited-coloplast-as_655516.html","title":{"rendered":"Microvascular Angina Clinical Trials, Growth, and Key Companies|Companies &#8211; Predictive Bioscience, Centogene GmbH, Pacific Edge Limited, Coloplast A\/S."},"content":{"rendered":"<div style=\"float:right; width:250px;\" class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Las Vegas Nevada United States), DelveInsight\u2019s &#8221;Microvascular Angina Pipeline Insight, 2023&#8243; report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across the Microvascular Angina market. A detailed picture of the Microvascular Angina pipeline landscape is provided, which includes the disease overview and Microvascular Angina treatment guidelines.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">(Las Vegas Nevada United States), DelveInsight&rsquo;s &#8221;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/microvascular-angina-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Microvascular Angina Pipeline Insight, 2023<\/a><\/strong>&#8221; report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across the Microvascular Angina market. A detailed picture of the Microvascular Angina pipeline landscape is provided, which includes the disease overview and Microvascular Angina treatment guidelines. The assessment part of the report embraces in-depth Microvascular Angina commercial assessment and clinical assessment of the Microvascular Angina pipeline products from the pre-clinical developmental phase to the marketed phase.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/microvascular-angina-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Takeaways from the Microvascular Angina Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading Microvascular Angina companies developing novel drug candidates to improve the Microvascular Angina treatment landscape include Abbott, Sanofi, Bristol Myers Squibb, Astellas Pharmaceuticals, Astrazeneca, GlaxoSmithKline, and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Promising Microvascular Angina pipeline therapies in various stages of development include Ranolazine, Nebivolol, Clopidogrel, Lercanidipine, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Microvascular Angina Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Microvascular angina (chest pain) is a type of angina that is caused by problems in the smallest blood vessels of the coronary arteries. The coronary arteries, which surround your heart, bring a constant supply of oxygenated blood to the hear<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/147690544871c126c1caee662674cbd4.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Discover more about the emerging Microvascular Angina drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/microvascular-angina-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Microvascular AnginaTreatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Microvascular Angina Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Abbott: Ranolazine<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Sanofi: Nebivolol<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Bristol Myers Squibb:Clopidogrel<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Astrazeneca:Lercanidipine<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Microvascular Angina Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage:&nbsp;Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Microvascular Angina Companies: Abbott, Sanofi, Bristol Myers Squibb, Astellas Pharmaceuticals, Astrazeneca, GlaxoSmithKline, and others<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Microvascular Angina&nbsp; Pipeline Therapies: Ranolazine, Nebivolol, Clopidogrel, Lercanidipine, and others<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Find out more about the Microvascular Angina&nbsp; treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/microvascular-angina-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Microvascular Angina Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Microvascular Angina Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Microvascular Angina Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Microvascular Angina Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Microvascular Angina Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Microvascular Angina Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Microvascular Angina Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Microvascular Angina Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Microvascular Angina Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Microvascular Angina Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Microvascular Angina Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Microvascular Angina Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Microvascular Angina Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Microvascular Angina Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Microvascular Angina Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=microvascular-angina-clinical-trials-growth-and-key-companiescompanies-predictive-bioscience-centogene-gmbh-pacific-edge-limited-coloplast-as\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=microvascular-angina-clinical-trials-growth-and-key-companiescompanies-predictive-bioscience-centogene-gmbh-pacific-edge-limited-coloplast-as\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP (Las Vegas Nevada United States), DelveInsight\u2019s &#8221;Microvascular Angina Pipeline Insight, 2023&#8243; report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across the Microvascular Angina market. A detailed picture of the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/microvascular-angina-clinical-trials-growth-and-key-companiescompanies-predictive-bioscience-centogene-gmbh-pacific-edge-limited-coloplast-as_655516.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-655516","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/655516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=655516"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/655516\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=655516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=655516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=655516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}